A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT06533644 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

PROCEDURE: Partial Oncolysis
DRUG: SV-102

Sponsor

Syncromune, Inc.